Article focus
=============

-   To determine the key histological and molecular changes in rotator cuff disease (RCD) by systematically reviewing the -scientific literature

Key messages
============

-   The pathogenesis of RCD is complex and multifactorial

-   The progressive histological changes in RCD are of a characteristic pattern

-   The levels of several molecular biomarkers are altered in RCD

Strengths and limitations
=========================

-   The studies of RCD are heterogeneous in several ways, including subject type and disease characteristics

-   The supraspinatus tendon is highly variable morphologically in terms of loading patterns, and this has a consequent effect on the local molecular biomarker levels

-   Understanding the changes in molecular biomarkers is paramount in guiding the future research and treatment of RCD

Introduction
============

Rotator cuff disease (RCD) involves a spectrum of shoulder conditions from early tendino-pathy to full thickness tears. The natural history and molecular pathophysiology of cuff disease is far from being fully understood. Historically the idea of mechanisms both intrinsic and extrinsic to the tendon have been researched and argued. Codman and Akerson^[@r1]^ initially proposed in 1934 that degeneration within the tendon was the 'intrinsic' primary cause of cuff tears. The 'extrinsic' theory relating to tendon damage secondary to attrition by surrounding -structures was popularised by Neer in 1972,^[@r2]^ and the term 'impingement' was coined. The pathogenesis of cuff disease is multifactorial and likely results from a combination of intrinsic, extrinsic and environmental factors.^[@r3]^

The rotator cuff insertion onto the humeral tuberosities is broad, continuous, multilayered and interwoven.^[@r4]^ The supraspinatus and infraspinatus tendons fuse 1.5 cm proximal to their insertions. Tears in the supraspinatus tendon (SST) are the most common and they are most frequently found near to the tendon's bony insertion; as SST tears become larger they are more likely to involve infraspinatus due to their common insertion. In this context the anatomy of the SST's insertion is of key relevance in terms of its extracellular matrix composition and has been categorised into four transition zones.^[@r5]^ The first zone is proper tendon, made up of largely type I collagen and small amounts of decorin. The second zone is fibrocartilage and consists of largely types II and III collagen, with small amounts of types I, IX and X collagen. The third zone is mineralised fibrocartilage and consists of type II collagen, with significant amounts of type X collagen and aggrecan. The fourth zone is bone and is largely type I collagen with a high mineral content. This effective bone-tendon attachment is achieved through a functional grading in mineral content and collagen fibre orientation. The SST enthesis is a highly specialised inhomogeneous structure that is subjected to both tensile and compressive forces; this appears important in both the development and propagation of cuff tears.

Tendon homeostasis and its failure in degenerative disease is a complex process that involves the interplay between a variety of cells, matrix components, enzymes, cytokines, growth factors and proteins. The roles of the different anatomical structures involved (the SST itself, the subacromial bursa (SAB) and the glenohumeral joint capsule (GHC)) are yet to be fully determined. The purpose of this systematic review was to summarise the cellular and molecular changes in rotator cuff disease and explain their possible significance in terms of the disease pathogenesis and future research.

Materials and Methods
=====================

This systematic review used the PRISMA-Statement (-Preferred Reporting Items for Systematic Reviews and Meta-Analyses) as a guideline in the development of the study protocol and the report of the current study.^[@r6]^ The inclusion criteria and methods of analysis were specified in advance and documented in a protocol.

Information sources and search strategy
---------------------------------------

Studies were identified by searching the PubMed and Cochrane electronic databases. The search was undertaken in April 2012. The following search terms were used in PubMed: shoulder nerve growth factor, shoulder NGF, shoulder neuronal regulation, shoulder neuropeptide Y, shoulder NPY, shoulder noradrenaline, shoulder VIP, shoulder Acetycholine, shoulder substance P, shoulder TGF, shoulder- CGRP, shoulder IB4, shoulder galanin, shoulder recept shoulder opio\*, shoulder histological, shoulder molecul\*, shoulder somatostatin, shoulder encephalin, shoulder endorphin, shoulder neurokinin, shoulder histamine, shoulder prostagland\*, shoulder NMDA, shoulder AMPA, shoulder glutam\*, shoulder collagen, shoulder matrix, shoulder GAG and Glycosamino\*, shoulder -proteoglycan, shoulder apoptosis, shoulder cytokines, shoulder chemokines, shoulder growth factor\*, shoulder VEGF, shoulder Interleuk\*, shoulder TIMP, shoulder metalloprot\*, shoulder MMP, shoulder ADAMT, shoulder TNF, shoulder tendinopathy\*, shoulder degenerative disease.

All searches were repeated with the word 'shoulder' being substituted by 'rotator cuff'. Additional studies were located by searching reference lists of short listed articles. Hand searches were undertaken on the British and American editions of the *Journal of Bone and Joint -Surgery* and the *Journal of Shoulder and Elbow Surgery*.

Study selection
---------------

The citations identified from the searches were combined and duplicates excluded. All citations for papers clearly referring to a topic other than the shoulder were excluded, as were others whose title clearly showed that the paper was not relevant to the -current study.

Full copies of the remaining papers were obtained and assessed. Papers concerning the cellular or molecular changes in degenerative RCD were included. Degenerative RCD included patients with asymptomatic age-related degeneration (ARD) and symptomatic patients including the diagnoses of subacromial bursitis, impingement syndrome (IS), rotator cuff tendinopathy, rotator cuff tear (RCT), calcifying tendinopathy (CT), long head of biceps (LHB) tendinopathy and cuff tear arthropathy.

Papers that studied cuff tear models and *in vitro* studies were excluded. Papers relating to animal overuse models and animal impingement models were included. Papers relating to non-degenerative conditions (such as frozen shoulder) were excluded unless the results for the patients with degenerative disease could be separated. Papers describing solely macroscopic changes, molecular changes that had no control groups for comparison, or relating to studies of any tissue or fluid not located in the region of the shoulder were excluded.

Data collection process
-----------------------

The descriptive histological results and molecular changes were recorded and have been summarised in Tables I, II and III; where the molecular change was within different RCD subgroups this was documented in the results.

Results
=======

Study selection and characteristics
-----------------------------------

The search strategy revealed a total of 6145 results (Fig. 1). After removal of duplicate entries, 3956 unique papers remained. Screening of the titles and abstracts revealed 190 papers eligible for inclusion. Further assessment of eligibility, based on full-text papers, led to the exclusion of 89 papers. This left 101 papers meeting our criteria for inclusion.^[@r1],[@r7]-[@r106]^

![Flow chart of systematic review protocol.](2000115-galleyfig1){#f1}

A total of 92 studies used exclusively human subjects, 12 of which used cadavers. Seven studies used exclusively animal overuse models (six rat and one dog model), and two studies used both human subjects and a model of animal overuse. The SST alone was analysed in 58 studies, SAB tissue alone in 16, while the other studies -analysed other tissue or varying combinations of tissue types. All studies analysed RCD in humans or the effects of overuse in an animal model. A total of 43 studies were exclusively histological, 36 studies exclusively molecular, while the remaining 22 analysed both histological and molecular changes. All studies on molecular changes had control groups or performed sub-group analyses based on specific subject characteristics. The types of control included those undergoing surgery for other reasons (instability/trauma), cadaveric specimens and subscapularis samples. A wide variety of techniques were used, including immunohistochemistry (IHC), reverse transcription polymerase chain reaction (RTPCR) and enzyme linked immunosorbent assays (ELISAs).

The histological changes in RCD are summarised in Table I. The significant molecular changes are summarised in Tables II and III.

###### 

Histological changes in rotator cuff disease (RCD)

                                 **Age-related changes (ARD)^\*^**                                     **Rotator cuff tendinopathy/ Impingement syndrome (IS)/ Calcific tendinopathy (CT)^†^**             **Rotator cuff tears (RCTs)^‡^**
  ------------------------------ --------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                           
  Cellular changes               Rounding of tenocyte nuclei^[@r16],[@r71],[@r101]^                    Rounding of tenocytes^[@r18],[@r86]^                                                                Rounding of tenocyte nuclei^[@r12],[@r52],[@r65],[@r69],[@r71]^
                                                                                                       Increased cellularity^[@r86],[@r94]^                                                                Plump mesenchymal cells present^[@r43]^
                                                                                                       Increased apoptosis^[@r12],[@r94]^                                                                  Increased cellular proliferation^[@r43],[@r54]^
                                                                                                       Bursal inflammatory cell infiltrate^[@r12],[@r55],[@r76]^                                           More variable cellularity^[@r52],[@r54],[@r65],[@r69],[@r85]^
                                                                                                       No bursal inflammatory cell infiltrate^[@r78]^                                                      Increased cellularity^[@r65]^ (in small RCT *vs* larger RCT^[@r56],[@r82]^)
                                                                                                       Macrophages and multinucleate cells located around areas of resorption in CT^[@r8],[@r95],[@r96]^   Increased apoptosis ^[@r12],[@r54],[@r58],[@r106]^ (α increasing degeneration^[@r102]^)
                                                                                                       Chondrocyte type cells^[@r8],[@r95],[@r96]^                                                         Inflammatory cell infiltrate,^[@r27],[@r82]^ no inflammatory cell infiltrate^[@r102]^
                                                                                                                                                                                                           Bursal inflammatory cell infiltrate^[@r12],[@r27]^(small \> large RCT^[@r58]^) (ftRCT \> ptRCT^[@r82]^)
                                                                                                                                                                                                           Lymphocyte infiltrate^[@r31]^
                                                                                                                                                                                                           Scanty T/B cells ^[@r12],[@r27]^
                                                                                                                                                                                                           
  Extracellular matrix changes   Loss of matrix organisation^[@r49],[@r71],[@r101]^                    Loss of matrix organisation^[@r8],[@r77],[@r86]^                                                    Loss of matrix organisation^[@r23],[@r30],[@r33],[@r52]-[@r54],[@r56],[@r65],[@r71],[@r77],[@r85],[@r102]^ (α tear size^[@r82]^)
                                 Fibrocartilagenous change^[@r1],[@r16],[@r20]^                        Increased mechanoreceptor numbers^[@r18]^                                                           Thinning of collagen fibres^[@r53],[@r92]^
                                 Mucoid/myxoid degeneration^[@r15],[@r19]^                             Fatty degeneration/infiltration^[@r78]^                                                             Fatty degeneration/infiltration^[@r23],[@r30],[@r31],[@r33],[@r43],[@r62],[@r78]^
                                 Fatty degeneration/infiltration^[@r15]^                               Fibrocartilagenous change around areas of calcification ^[@r78],[@r95],[@r98]^                      Focal areas of tissue necrosis^[@r23],[@r30],[@r85],[@r92]^
                                 Increased GAG^[@r16]^                                                                                                                                                     Mucoid/myxoid degeneration ^[@r31],[@r33],[@r57],[@r58],[@r60],[@r106]^
                                 Calcified deposits^[@r1],[@r16],[@r20]^                                                                                                                                   Calcified deposits^[@r30],[@r31],[@r33]^
                                                                                                                                                                                                           Procollagen type I at tear margins^[@r32]^
                                                                                                                                                                                                           Amyloid deposition^[@r17]^
                                                                                                                                                                                                           
  Vascularity                    Increased vascularity^[@r20]^                                         Increased vascularity^[@r94]^                                                                       Focal areas of increased vascularity^[@r22],[@r69],[@r85]^ (α increasing degeneration ^[@r102]^)
                                                                                                       Bursal vascular proliferation^[@r55]^                                                               Increased vascularity^[@r45],[@r52],[@r65]^
                                                                                                                                                                                                           Vascular proliferation^[@r33],[@r43],[@r54]^
                                                                                                                                                                                                           Unchanged overall vascularity^[@r24]^
                                                                                                                                                                                                           Increased bursal vascularity (RCT *vs* non-RCT^[@r36]^) (ftRCT *vs* ptRCT^[@r82]^)
                                                                                                                                                                                                           Increased LHB vascularity in RCT^[@r46]^
                                                                                                                                                                                                           
  Overall change                 Increased general degeneration^[@r34],[@r49],[@r71],[@r72],[@r101]^   Increased general degeneration^[@r94]^                                                              Increased general degeneration ^[@r54],[@r57]-[@r60],[@r71],[@r106]^
                                 Chondroid metaplasia^[@r15],[@r19]^                                   Chondroid metaplasia^[@r12]^                                                                        Chondroid metaplasia ^[@r12],[@r22],[@r23],[@r33],[@r53],[@r56]-[@r58],[@r60]^
                                 Hyaline degeneration^[@r71]^                                          Increased bursal fibrosis^[@r35],[@r55],[@r70]^                                                     Hyaline degeneration^[@r33],[@r52],[@r65],[@r71]^
                                 Reduced cellularity^[@r20]^                                           Increased LHB degeneration^[@r39]^                                                                  Fibrocartilagenous/granulation tissue at tear edges^[@r22],[@r23],[@r27],[@r30],[@r43],[@r56],[@r92]^
                                 Failed tendon healing^[@r1]^                                          Increased bursal reaction^[@r55],[@r78],[@r99],[@r104]^                                             Increased bursal fibrosis^[@r35]^
                                 Glenohumeral joint degeneration increased with RCTs^[@r20],[@r34]^    Degeneration of acromion under surface/CAL^[@r77],[@r95]^                                           Increased bursal reaction^[@r56],[@r78],[@r99],[@r104]^ (ftRCT \> ptRCT^[@r36]^)
                                 Degeneration of -acromion under -surface/CAL^[@r62],[@r67],[@r81]^    Lower number of axons innervated LHBT^[@r84]^                                                       Glenohumeral joint synovial inflammation^[@r28]^
                                                                                                                                                                                                           Increased subscapularis tendon degeneration^[@r60]^
                                                                                                                                                                                                           Degeneration of acromion under surface/CAL^[@r77],[@r95]^ (RCT \> non-RCT^[@r67],[@r90]^)
                                                                                                                                                                                                           Supraspinatus muscle fatty infiltration/degeneration^[@r87]^
                                                                                                                                                                                                           

\* GAG, glycosaminoglycan; CAL, coracoacromial ligament † LHB, long head of biceps; LHBT, long head of biceps tendinopathy ‡ ft, full-thickness; pt, partial thickness

###### 

The changes to extracellular matrix (ECM) components and enzymes in rotator cuff disease (RCD) (also includes changes to other enzymes and transcription factors) (↑, increased; ↓, decreased)

  **Matrix components**                                                                          **Matrix enzymes**
  ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
                                                                                                 
  Type I collagen ↑^[@r50]^                                                                      MMP-1 ↑^[@r14],[@r27],[@r40],[@r45],[@r47],[@r66],[@r99]^ ↓^[@r48]^
  Type II collagen ↑^[@r23],[@r67]^                                                              MMP-2 ↑^[@r66]^ ↑ (ftRCT *vs* ptRCT^[@r89]^)
  Type III collagen ↑,^[@r10],[@r39],[@r43],[@r50],[@r72],[@r74]^ ↑ (RCT *vs* non-RCT^[@r36]^)   MMP-3 ↑^[@r39],[@r66]^ ↓^[@r45],[@r47],[@r48],[@r51]^ ↑ (ftRCT *vs* ptRCT^[@r105]^
  Type X collagen ↑^[@r67]^                                                                      MMP-9 ↑^[@r14],[@r45],[@r47],[@r82],[@r99]^ ↑ (ftRCT *vs* ptRCT^[@r89]^)
  Type I collagen α1 ↓^[@r9]^ ↑ (ftRCT *vs* ptRCT^[@r82]^)                                       MMP-13 ↑^[@r37],[@r48],[@r51],[@r66],[@r82]^
  Type I collagen α2 ↓^[@r7],[@r38]^                                                             TIMP-1 ↓^[@r51]^
  Type II collagen α1 ↑^[@r7],[@r9],[@r38]^                                                      TIMP-2 ↓^[@r51]^
  Type III collagen α1 ↑^[@r9],[@r93]^ ↓^[@r7]^                                                  TIMP3 ↓^[@r7],[@r38]^
  Type VI collagen ↑^[@r8]^ α1 ↑^[@r9]^                                                          ADAM10 ↓^[@r7]^
  Collagen crosslinking ↑^[@r10]^                                                                Transglutaminase 2 ↓^[@r65]^
  Total collagen content ↓^[@r10],[@r72],[@r74]^                                                 
  Calcium phosphate ↑^[@r72]^                                                                    
  Aggrecan ↑^[@r7],[@r9],[@r38],[@r50]^                                                          **Other enzymes**
  Biglycan ↑^[@r9]^                                                                              COX-1 ↑^[@r14],[@r99]^
  Decorin ↑^[@r9]^ ↓^[@r7],[@r50]^                                                               COX-2 ↑^[@r14],[@r68],[@r82],[@r99]^
  Clusterin ↑^[@r7],[@r58]^                                                                      Cathepsin D ↑^[@r27]^
  Elastin ↓^[@r7]^                                                                               iNOS ↑^[@r82],[@r88]^
  Fibronectin ↑(RCT *vs* non-RCT^[@r92]^)                                                        eNOS ↑^[@r88]^
  Osteopontin ↑^[@r91]^                                                                          
  Tenascin-C ↑^[@r23],[@r35]^                                                                    
  Versican ↑^[@r9]^                                                                              **Transcription factors**
  GAG content ↑^[@r9],[@r72]^                                                                    SOX9 ↑^[@r7],[@r9]^
     Chondroitin sulphate ↑^[@r8],[@r23],[@r72],[@r73]^                                          FOXO1A ↑ (massive tears ^[@r80]^)
     Dermatan sulphate ↑^[@r8],[@r72],[@r73]^                                                    FOXO3A ↑ (in tears greater than one-third^[@r80]^)
     Hyalauronan ↑^[@r73]^                                                                       
     Hyaluronic acid ↑^[@r73]^                                                                   
  α-skeletal muscle actin and of myosin heavy polypeptide1 ↑^[@r21]^                             

###### 

The changes to cytokines, growth factors, neuronal factors, apoptosis/cell cyle related factors and other factors in rotator cuff disease (RCD) (↑, increased; ↓, decreased)

  **Cytokines/growth factors**                                                                                           **Apoptosis/cell cycle related**
  ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                         
  IL-1α ↑^[@r14],[@r99]^                                                                                                 HIF-1α ↑^[@r11],[@r45],[@r58]^ ↓^[@r59],[@r60],[@r61]^
  IL-1ra ↑^[@r26]-[@r28]^                                                                                                BNIP-3 ↑^[@r11]^
  IL-1β ↑^[@r13],[@r14],[@r26]-[@r28],[@r42],[@r75],[@r82],[@r99]^                                                       BCL-2 ↑^[@r58]^
  IL-2 ↓^[@r60],[@r61]^                                                                                                  Caspase 3 ↑^[@r59],[@r60]^
  Il-6 ↑^[@r13],[@r14],[@r42],[@r60],[@r82],[@r99]^                                                                      Caspase 8 ↑^[@r59]-[@r61]^
  IL-11 ↑^[@r60],[@r61]^                                                                                                 Heat shock protein 27 ↑^[@r59]-[@r61]^
  Il-15 ↑^[@r60]^                                                                                                        Heat shock protein 70 ↑^[@r59]-[@r61]^
  Il-18 ↑^[@r60]^                                                                                                        poly(ADP-ribose) polymerase ↑^[@r60],[@r61]^
  Stromal derived factor-1α (SDF-1α) ↑^[@r13],[@r41]^)                                                                   type-2 angiotensin II receptor ↓^[@r60],[@r61]^
  TNFα ↑^[@r14],[@r42],[@r75],[@r82],[@r99]^                                                                             cFLIP ↑^[@r59]^
  VEGF ↑^[@r45],[@r46],[@r58],[@r68],[@r82]^ ↑ (associated with motion pain^[@r104]^)                                    cFLIP receptor ↑^[@r60]^
  IGF-1 ↓^[@r7],[@r38]^                                                                                                  p-53 induced gene I, cell division cycle 25A, Max protein, meiotic recombination 11 homolog A ↑^[@r61]^
  TGF-β ↑^[@r67],[@r75]^                                                                                                 Peroxiredoxin 5 ↑^[@r100]^
  bFGF ↑^[@r67],[@r75]^                                                                                                  P53 ↑^[@r54],[@r61]^
  FGF 18 ↑^[@r61]^                                                                                                       P53 inhibitors ↓^[@r54]^
  BMP2 and BMP7 ↑^[@r67]^                                                                                                NF-κB ↓^[@r54]^
  Small inducible cytokines ↑^[@r14]^                                                                                    Receptor activator of NF-κB ↑^[@r60]^
  Macrophage inhibitory factor (MIF) ↑^[@r60]^                                                                           
  Heparin affinity regulatory peptide (HARP) ↑^[@r9]^                                                                    
  Five-lipoxygenase activating protein ↑^[@r68]^                                                                         
  Hepatocyte growth factor ↓^[@r61]^                                                                                     
                                                                                                                         
  **Neuronal factors**                                                                                                   **Others**
  Substance P ↑^[@r40]^ (higher in non-perforated RCTs *vs* perforated^[@r25]^)                                          Ubiquitin proteasome pathway UBE2A and UBE3A ↑ (massive tears *vs* small/controls^[@r80]^)
  β-endorphin ↑^[@r40]^                                                                                                  Calpain (CAPN1) and CTSB (lysosomal enzyme) ↑ (massive tears *vs* small/controls^[@r80]^)
  Anti-NGF30 ↑^[@r60],[@r61]^                                                                                            vWF ↑^[@r68]^
  PGP9.5, GAP43 ↑^[@r103]^                                                                                               T-cell receptor variable βchain ↑^[@r60]^
  glutamate receptor 5, glutamate receptor metabotropic 6, glutamate receptor inotropic 3A, GABA receptor α1 ↑^[@r61]^   Ig heavy chain, T cell receptor α chain ↓^[@r60]^
  AMPA1, glutamate receptor interacting protein 1/2 ↓^[@r61]^                                                            GATA binding protein, PAF acetylhydrolase, Attractin, IgG-2b chain ↑^[@r60],[@r61]^
                                                                                                                         Insulin induced gene 1, FGFr1, nuclear receptor -coactivator 2, G protein coupled receptor 54, Ephrin A1, Thyrotroph embryonic factor, Odd Oz/ten-m homolog 2, POU domain, TNF 11, TGF-β binding -protein 3, T cell receptor β chain, cytochrome b-245, CD3 γ chain, polyprotein 1-microglobulin, Fc receptor IgE, solute carrier family 2, adenosine deaminsae, -integrin-linked kinase ↑^[@r61]^
                                                                                                                         Dynein, nuclear receptor subfamily 2 group F member 1, Homeobox A1, FGF receptor 3, MHC class I-like sequence, T-cell receptor β chain, killer cell lectin-like receptor, strain T-cell receptor ↓^[@r61]^
                                                                                                                         T-cell receptor ↓^[@r60],[@r61]^

A reduction in overall collagen content and were seen in RCD; type II and III collagen content were increased in multiple studies. Overall glycosaminoglycan (GAG) levels were increased, while certain proteoglycans levels were increased (tenascin-C, fibronectin, aggrecan, and biglycan) and others reduced (elastin). The general in RCD was towards a fibrocartilagenous phenotype.

The collagenases matrix metalloproteinase (MMP)-1 and -13 were increased in RCD, while the gelatinases MMP-2 and MMP-9 were also increased in RCD. MMP-3 levels were altered in seven studies, being increased in three and decreased in four. Tissue inhibitor of metalloproteinases (TIMP)-1, -2 and -3 have all been shown to be decreased in RCD, while no change in TIMP-4 was demonstrated. Overall there is a clear catabolic trend in RCD.

The changes in terms of cytokines were generally pro-inflammatory. Several members of the Interleukin family were increased in RCD (Interleukin-1α, 1β, -6, 11, 15, 18 and IL1-receptor antagonist). Tumour necrosis factor (TNF)-α, stromal derived factor-1α and the small inducible cytokines were all increased. The cyclo-oxygenases (1 and 2), Cathepsin D and nitric oxide synthase were all increased in RCD. Several growth factors were increased in RCD including vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β, fibroblast growth factor (FGF), bone morphogenetic protein (BMP) 2 and BMP 7. Insulin-like growth factor (IGF)-1 was decreased in RCD.

Several proteins associated with apoptosis are increased in RCD, including p53, poly(ADP-ribose) polymerase, -caspases 3/8, B-cell lymphoma (BCL)-2, BNIP3, type II angiotensin receptor, cFLIP and cFLIP receptor. Peroxiredoxin 5 and the heat shock proteins 27/70 were increased, while there was no obvious trend in hypoxia-inducible factor (HIF)-1α levels; these substances may all play a protective role for cells at times of high stress. In terms of neuropeptides, increases in substance P and β-endorphin were seen in RCD. The increase in PGP9.5 and GAP43 is likely to represent neoinnervation in RCD.

Discussion
==========

The results of this systematic review must be seen in the context of the heterogeneity of the studies and of RCD in general. RCD includes a whole spectrum of changes to the histological and molecular characteristics of the -tissue. Different studies analysed the tissue of patient groups that were highly variable in terms of disease stage, symptomatology and patient demographics. It has been shown that significant molecular differences are found depending on if the sampled tendon is from an over-stressed or stress-shielded region.^[@r107]^ Several studies used animal overuse models which are hypothesised to mimic the pathophysiology of RCD, however there are likely to be some significant differences between the molecular changes found in these models and RCD in humans. There was also significant diversity between studies in terms of what was measured. Some studies measured molecular biomarker levels directly, some measured the gene expression of molecular biomarkers using mRNA and some used both of these techniques. All these factors may account for some of the apparent discrepancies in the study findings.

The cellular changes that occur as cuff disease progresses have been well described.^[@r12],[@r56]^ Small tears of the rotator cuff show features consistent with an attempt to heal such as increased fibroblast cellularity, blood vessel proliferation and the presence of a significant inflammatory component. These features of attempting healing diminish as the size of the tear and the amount of tendon degeneration increase. The progressive tendon degeneration is characterised by thinning of the collagen fibres, a loss of collagen structure, myxoid degeneration, hyaline degeneration, chrondroid metaplasia and fatty infiltration.^[@r33]^ The overall picture is one of pathological -chondroplasia in which tissue which normally exhibits a tensional morphology is replaced by tissue of a fibro-cartilage-like phenotype.^[@r23]^

The regulation of matrix turnover involves several cell types and numerous cytokines. The tenocyte is the resident fibroblast present in tendon and is arguably the most pivotal cell type; other cells involved include extrinsic fibroblasts and inflammatory cells such as the macrophage. Tenocytes have been shown to produce a number of cytokines in response to increased strain such as -Interleukin-1β (IL-1β), Interleukin-6 (IL-6), VEGF, HIF-1α, TGF-β and prostaglandin-E2 (PG-E2).^[@r108]-[@r111]^ Our results show that numerous cytokines and growth factors including IL-1β, IL-6, VEGF, bFGF, TGF-β, TNF-α, HIF-1α, cyclooxygenase (COX)-1, COX-2 and nitric oxide synthase (NOS) are all increased in RCD. VEGF, IGF-1, TGF-β and FGF are all increased during normal tendon healing^[@r112]^and their increase in RCD is demonstrative of tendon attempting to heal. An increased IL-1β production has been hypothesised to promote cell survival in a high stress environment.^[@r109]^ Numerous complex interactions occur between these cytokines, the extracellular matrix synthesis, catabolic mediators and cytoskeleton assembly.^[@r113]^ Pro-inflammatory cytokines affect extracellular matrix homeostasis, accelerate remodelling, amplify biomechanical adaptivity and promote tenocyte apoptosis. The trend towards a pro-inflammatory state in RCD is indicative of the imbalance that occurs between the catabolic and anabolic systems, the cytokines being key regulatory factors of these. As RCD progresses and cuff tears become increasingly sizeable there is a clear increase in apoptosis, as evidenced by increases in several apoptosis related markers including BNIP-3, BCL-2, the -caspases and the heat shock proteins. The increase in p53 activity in RCD may also be important in promoting -apoptosis.

Tendon is highly mechanically adaptive and a characteristic feature of RCD is the progressive mechanical failure of tendon to meet the physical demands placed upon it.^[@r112]^ Total collagen content decreases, while there is a significant increase in the proportion of type II and III collagen relative to type I collagen. This change in collagen makeup goes hand in hand with a transformation of the matrix from larger organised fibrils to smaller disorganised fibrils with decreasing mechanical properties. The mature and hydroxylysine cross-links are significantly increased which may be a feature of the incomplete remodelling found in scar tissue.^[@r10]^ The increase in the glyco-proteins tenascin-C and fibronectin is consistent with a wound healing process occurring in degenerate tendon. The changes to several different proteoglycans in RCD are varied but the overall picture appears to be of fibro-cartilagenous change; this is characterised by increased aggrecan and biglycan, with decreased -decorin. Therefore overall the matrix changes are consistent with the degenerate tendon attempting to heal, with a progressively mechanically weak scar tissue being laid down as part of this failing remodelling process.

Higher levels of matrix remodelling and turnover have been linked with RCD^[@r114]^ and the tissue-degrading enzymes of the metalloproteinase family are important in this process. The family includes the MMPs, their close relatives 'a disintegrin and metalloproteinase' (ADAMs) and 'a disintegrin and metalloproteinase with thrombo-spondin motifs' (ADAMTS). The MMP family consists of 24 known MMPs including the collagenases (MMP1, -8 and -13), the gelatinases (MMP-2 and -9), membrane-type MMPs (MT-MMPs), the stromelysins (MMP-3 and -10 and the matrilysins (MMP-7 and -26).^[@r115]^ The collagen-ases, as well as MMP-2 and -14, have important collagen-olytic activity. The ADAMTS are divided into four groups, of which ADAMTS -1,-4,-5,-8,-9,-15,-20 are the aggre-canases and ADAMTS -2,-3,-14 are the procollagen N\--proteinases. The TIMPs are endogenous inhibitors of the metalloproteinases and there are four in humans; they reversibly inhibit all MMPs by a 1:1 interaction with the zinc binding site. The MMPs do not solely degrade tissue; they may have anti-inflammatory actions by processing certain cytokines and chemokines.^[@r114]^

The increased collagen turnover in RCD is consistent with the increase in two collagenases (MMP-1 and -13) and two gelatinases (MMP-2 and -9). MMP-3 is thought to be important in the regulation of matrix turnover and is reduced in the degenerate SST; this is consistent with tendinopathy resulting from a failure in tendon repair or matrix maintenance. The decreases in TIMP-1,-2, and -3 in RCD are also consistent with this catabolic picture of increased matrix degradation and failing remodelling. The roles of the ADAMs and ADAMTS have yet to be determined in RCD. Older tendon is more susceptible to mechanically induced failure involving MMP activity^[@r116]^ and this may be related to age-related change in -tenocytes.^[@r117]^ The role of tendon stem cells (TSCs) remains to be determined but their responses to differing mechanical stimuli hint towards an important role.^[@r118]-[@r120]^ TSCs have been shown to proliferate and produce collagen in response to exercise, while they have been shown to differentiate into non-tenocytes if excessively mechanically loaded. A recent report suggested that an extracellular matrix rich niche, organised partly by biglycan and fibromodulin, controls the self-renewal and differentiation of TSCs.^[@r121]^ The self-renewal capacity and differentiation capability of TSCs reduces with increasing age^[@r122],[@r123]^ and this is likely to be important in explaining the age-related nature of RCD.

This review has summarised just how much progress has been made in recent years, particularly in the advent of modern molecular medical techniques. Intrinsic, extrinsic and environmental factors all have an important role to play in the disordered tendon homeostasis of RCD which can lead to progressive mechanical failure. Among the key questions that remain to be answered include why some patients' tendons degenerate, while others do not, and why some patients experience pain, while others with the same amount of macroscopic tendon degeneration do not. Certainly there is still a great deal to be understood as regards the pathogenesis of RCD and undoubtedly, unlocking these secrets could pave the way for some very exciting new treatments in the future.

Supplementary Material
----------------------

###### 

A table giving details of each of the 101 studies included in this review is available with this article on our website www.bjr.boneandjoint.org.uk
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